Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bria-OTS
- Development stage
- Unknown
- Lead developer
- BriaCell Therapeutics
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Bria-OTS is a personalized, "off-the-shelf" cellular immunotherapy developed by BriaCell Therapeutics for the treatment of advanced solid tumors, primarily metastatic breast cancer. As a next-generation version of the Bria-IMT platform, Bria-OTS consists of genetically engineered human breast cancer cell lines (such as the BC1 line) that are matched to a patient's HLA type. These cells are engineered to express exogenous MHC class II alleles and immune-stimulating cytokines, acting as a personalized tumor cell vaccine that activates the patient's immune system to recognize and destroy cancer cells. The therapy is typically administered as part of a regimen that includes low-dose cyclophosphamide and peginterferon alpha-2a. Bria-OTS is currently being evaluated in Phase 1/2 clinical trials both as a monotherapy and in combination with immune checkpoint inhibitors such as tislelizumab.
- Brand names
- Bria-OTS
- Other names
- Bria-OTS immunotherapyBria-OTS platform
Beyond the preview
Go deeper on Bria-OTS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bria-OTS.